BioMarin Welcomes Arpit Davé as New Chief Digital and Information Officer

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global leader specializing in rare diseases, has recently announced the appointment of Arpit Davé as its new Executive Vice President and Chief Digital and Information Officer, a pivotal role that reports directly to the President and CEO, Alexander Hardy. This strategic appointment reflects BioMarin's commitment to enhancing its digital transformation and technology strategy in the biopharmaceutical industry.

Arpit Davé brings over two decades of extensive experience in the biopharmaceutical sector, particularly focusing on information technology, digital transformation, and artificial intelligence. His proven track record in propelling organizations towards measurable growth through technology will be essential in reimagining the enterprise technology framework at BioMarin. Mr. Davé's career has been marked by meaningful contributions to leading patient-centric initiatives that prioritize business profitability alongside improving patient outcomes.

Before joining BioMarin, Davé spent seven and a half years at Amgen, Inc., where he played a crucial role as a technology executive. His responsibilities included driving digital transformations that enhanced operational efficiencies and solidified Amgen's competitive edge in a rapidly evolving AI landscape. Additionally, Mr. Davé’s prior experience includes significant leadership roles at renowned companies, such as Bristol Myers Squibb and Merck, where he focused on data science and research and development, demonstrating his robust understanding of the industry.

A graduate of the University of Texas with a Master's degree in Industrial Engineering, Davé also holds a Bachelor's degree in Mechanical Engineering from S.P. University in India. His academic background, combined with his practical experience, positions him uniquely to contribute to BioMarin's vision.

In his new role at BioMarin, Davé is tasked with developing and executing the organization’s comprehensive technology strategy. This will include leveraging data science and digital capabilities not only to advance internal operations but also to enhance drug development processes and improve the overall quality of care for patients living with rare diseases. “Arpit is a visionary thinker and a talented leader,” said Alexander Hardy. “He brings a wealth of experience and a deep understanding of how technology can be used to deliver real value to both patients and our business.”

Davé expressed his enthusiasm for joining BioMarin at a crucial juncture, noting the extraordinary potential at the intersection of biology, data, and AI. “I have long admired BioMarin's commitment to serving those with rare diseases,” he said. “I am eager to collaborate with our world-class teams to unlock new opportunities and accelerate the delivery of transformative therapies to the patients who rely on us.”

BioMarin Pharmaceutical, founded in 1997 and situated in San Rafael, California, is recognized for its innovative approach to drug discovery and development. The company focuses on developing pioneering medicines for genetically defined conditions and has a robust pipeline comprising eight commercial therapies, demonstrating its dedication to improving lives through biotechnology.

With Davé's appointment, BioMarin is poised to enhance its operations, streamline research and development efforts, and deliver advanced therapeutics more effectively to patients around the globe. The healthcare landscape, particularly concerning rare diseases, stands to benefit from the technological advancements facilitated by this leadership change, marking a significant milestone in BioMarin's ongoing journey to better serve its stakeholders.

As a forward-looking biopharmaceutical company, BioMarin continues to navigate the evolving challenges of the industry, and with leaders like Arpit Davé at the helm of digital innovation, the company aims to maintain its role as a trailblazer in the biotech space.

For further information about BioMarin and its latest innovations, visit www.biomarin.com.